Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder

Contributed by: GlobeNewswire

Tags

Biotechnology

More Like This

Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

Topflight Pharma Development Veteran Joins Synendos

MindMed Announces Business Update and Anticipated Milestones for 2024

MindMed to Present at Upcoming May Medical Conferences

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder